Shots:

• The collaboration will evaluate RNAi therapeutics targeting three host factors required for SARS-CoV-2 infection- including ACE2 and TMPRSS2. The third target is expected to emerge from Vir’s ongoing genomics efforts for identifying novel host factors relevant to COVID-19
• Under the amended collaboration- Vir will be responsible for the development of selected DCs and the commercialization of any therapy- developed under the collaboration. Alnylam will either have an option to share equal profits & losses associated with each COVID-19 program or may receive milestones & royalties emerging from the collaboration
• The additional targets expanded the companies’2017 collaboration and the amendment to that agreement announced in Mar 2020- to now develop novel siRNAs for up to 9 infectious disease targets

Click here to­ read full press release/ article | Ref: Alnylam | Image: Alnylam